The DILfrequency study is an adaptive trial to identify optimal IL-2 dosing in patients with type 1 diabetes

BACKGROUND. Type 1 diabetes (T1D) results from loss of immune regulation, leading to the development of autoimmunity to pancreatic β cells, involving autoreactive T effector cells (Teffs). Tregs, which prevent autoimmunity, require IL-2 for maintenance of immunosuppressive functions. Using a respons...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:JCI Insight
Main Authors: Seelig, Eleonora, Howlett, James, Porter, Linsey, Truman, Lucy, Heywood, James, Kennet, Jane, Arbon, Emma L., Anselmiova, Katerina, Walker, Neil M., Atkar, Ravinder, Pekalski, Marcin L., Rytina, Ed, Evans, Mark, Wicker, Linda S., Todd, John A., Mander, Adrian P., Bond, Simon, Waldron-Lynch, Frank
Format: Artigo
Jezik:Inglês
Izdano: American Society for Clinical Investigation 2018
Teme:
Clinical Medicine
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC6237447/
https://ncbi.nlm.nih.gov/pubmed/30282826
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/jci.insight.99306
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki